Navigation Links
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
Date:6/30/2009

- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program -

- Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer Utility -

TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed the planned patient enrollment in its U.S. Phase I clinical trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. In a presentation of preliminary data from this trial at the 2009 ASCO Annual Meeting last month, the study's principal investigator at MD Anderson Cancer Center reported that bavituximab was generally safe and well-tolerated, with a predictable pharmacokinetic profile. In these patients, a maximum tolerated dose had not been reached even at the highest planned dose level. Peregrine has now begun designing additional bavituximab cancer trials based on findings from this Phase I study and the company's ongoing Phase II combination therapy trials in breast and lung cancer.

"Completion of patient enrollment in this Phase I trial is a significant milestone for the bavituximab cancer program," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "We believe data from this study, along with our ongoing Phase II lung and breast cancer trials, set the stage for advancing the bavituximab oncology program into later-stage clinical studies. The safety data collected from the diverse cancer types in this study are encouraging as we plan for expansion of the bavituximab cancer program in the coming year. We look forward to sharing more data from the ongoing cancer trials as patient treatment and follow-up continue in this study and in our three ongoing Phase II bavituximab cancer tri
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 01, 2015 The panel session ... telematics service providers to build a program that can ... complicated legal implications further down the line. This topic ... of the news that OBD-II port dongles aren’t as ... In January, it was reported that Progressive’s Snapshot dongles ...
(Date:4/1/2015)... Baby Bellies & Beyond Baby Expo, the ... the top products and services to new and expecting ... title for "Mommy Moments” - the largest gathering of ... Bellies & Beyond Expo Orlando on Sunday, April 19th. ... will commence at 11:00am with actual record counting beginning ...
(Date:4/1/2015)... 2015 BioPlus Specialty Pharmacy ... has released a new app to keep health care ... chronic hepatitis C virus (HCV) infection. This ‘HCV Treatment ... from the American Association for the Study of Liver ... new direct-acting oral medications to treat HCV have been ...
(Date:4/1/2015)... 2015 Dr. Daniel C. Stewart ... April to discuss the benefits of the LANAP® treatment ... from periodontal disease. People who live in Howard County, ... disease can now visit Dr. Stewart, a Maryland dentist, ... With the LANAP® protocol, which is a laser gum ...
(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
Breaking Medicine News(10 mins):Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 2Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3
... high levels of maternal DNA in the blood of around ... maternal stem cells also seemed to help in producing insulin, ... and even help to restore damaged tissue in the pancreas. ... by the child's immune system. ,During pregnancy, ...
... of subjecting adult patients to rapid flu diagnostic tests, which ... perhaps the first study of its kind to evaluate the ... published in the Archives of Internal Medicine. , ,A ... that 86 percent of adult patients diagnosed with the flu ...
... from an international group of eating disorders say ... "cause" eating disorders is like blaming// parents for ... ,Recent damaging statements by fashion model Gisele Bundchen ... perpetuate misconceptions and further stigmatize eating disorders. ...
... activity patterns of thousands of individuals living in different ... clock becomes coupled to so-called local sun time despite ... a common "social time" that is determined by time ... city dwellers appear to experience a relatively decreased influence ...
... drug plans between politicians and the common man. The finding ... common Canadian gets// only a partial cover under the public ... a formidable body, that takes the cause of seniors forward, ... drug plans of elected and public officials, with that of ...
... Simon Carding, has genetically altered or designed bacteria in ... , The bacterium ; Bacterium ovatus, one of the ... produce human growth factors called cytokines. These were used ... by the disease, hence reducing the inflammation. ,While ...
Cached Medicine News:Health News:'Families' - Doesn’t Cause Anorexia Nervos 2Health News:'Families' - Doesn’t Cause Anorexia Nervos 3Health News:Chronotype, a Measure to Assess Patterns of Daily Activities 2Health News:‘Sweet Revenge’ on Inflammatory Bowel Disea 2
(Date:4/1/2015)... According to a new market ... Plastic and Reconstructive Surgery, Oncology, Ophthalmology, Gynaecology & Urology, ... Global Forecast to 2020", published by MarketsandMarkets, the Surgical ... 2020 from $402.2 Million in 2014, at a CAGR ... Browse   7 6   ma rket ...
(Date:4/1/2015)... 1, 2015 Eli Lilly and Company (NYSE: ... quarter of 2015 on Thursday, April 23, 2015.  Lilly will ... investment community and media to further detail the company,s financial ... a.m. EDT. Investors, media, and the general public can access ... that will be posted on Lilly,s website at www.lilly.com ...
(Date:4/1/2015)... , April 1, 2015 International Isotopes ... for fiscal year ended December 31, 2014.  The Company ... in net loss, and positive cash flow for the ... Total revenue in 2014 was approximately $7.5 million compared ... increase of approximately 10%.  With the exception of the ...
Breaking Medicine Technology:Surgical Microscopes Market Worth $806.6 Million by 2020 2Surgical Microscopes Market Worth $806.6 Million by 2020 3Surgical Microscopes Market Worth $806.6 Million by 2020 4Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement 2International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7
... first time, an international panel of experts has ... Laparoscopic Sleeve Gastrectomy, a rapidly growing bariatric surgical ... The panel, made up of 25 ... help the surgical community continue to improve patient ...
... The report " In-Vitro Diagnostic (IVD) Market ... Emerging Markets   -   G7, Japan & BRIC) (2011 ... and studies the major market drivers, restraints, and opportunities in ... Browse market data tables and in-depth TOC ...
Cached Medicine Technology:International Panel of Leading Bariatric Surgeons Reaches Consensus on Optimal Techniques for Laparoscopic Sleeve Gastrectomy 2MarketsandMarkets: Global In-Vitro Diagnostic (IVD) Market Expected to Reach $64 Billion by 2016 2MarketsandMarkets: Global In-Vitro Diagnostic (IVD) Market Expected to Reach $64 Billion by 2016 3
Disposable Microscissors: Vertical, 90...
Popular D.O.R.C. vertical scissors redesigned for ease of entry through the sclerotomy and more precise cutting action. Rounded lower edge of scissors blade minimizes unintentional engagement of reti...
Sharp tipped scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and all purpose...
... The Focus Diagnostics Rickettsia Indirect ... is intended for the detection ... class antibodies to Spotted Fever ... as an in vitro aid ...
Medicine Products: